• Evaxion created a genetic adjuvant technologies that boosts the immune responses of viral, bacterial and cancer vaccines
• Preclinically validated for each DNA and mRNA vaccines, and prepared for clinical testing  
• Anticipated massive marketplace prospective for DNA and mRNA vaccines against cancer, viral and bacterial illnesses

COPENHAGEN, Denmark, May possibly 25, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology corporation specializing in the discovery and improvement of AI-powered immunotherapies, now unveils the technologies behind its novel, proprietary genetic adjuvant created to boost the effectiveness of DNA and mRNA vaccines for infectious illnesses and cancer. 

Most current information from the adjuvant plan have been presented at Evaxion’s reside stream R&ampD Day, May possibly 25, 2023. 

“We are excited to present this novel genetic adjuvant technologies to the worldwide scientific neighborhood. It boosts Evaxion´s personal DNA technologies and has the prospective to enhance the impact of practically any vaccine. We foresee a excellent marketplace prospective in that this technologies seems to be hugely productive in each DNA and mRNA primarily based vaccines against cancer as nicely as infectious illnesses,” stated Per Norlén, CEO at Evaxion. 

Evaxion´s novel genetic adjuvant carries the code for CCL19, a molecule recognized to attract immune cells, notably antigen presenting cells, and can be encoded into either DNA or mRNA vaccines with the aim of boosting the immune response. 

Most current information show that the genetic adjuvant technologies boosts the antitumor impact in preclinical tumor models, and induces neutralizing antibodies and T-cell responses against each viral and bacterial antigens: 

Per Norlén continues, “By encoding the immune-stimulating molecule CCL19 into either DNA or mRNA vaccines, we have demonstrated substantial enhancement of the vaccines effectiveness. We think that this advancement holds immense prospective for vaccine improvement, as it boosts each B cell and T cell immune responses, producing it applicable to a wide variety of vaccines. Constructing on the encouraging preclinical benefits, the subsequent step is to validate the technologies in individuals.” 

Evaxion aims to bring the genetic adjuvant technologies into clinical trials later this year as element of the customized cancer immunotherapy plan EVX-03.  

Please take a look at the Investors section of Evaxion’s web-site to access a replay of the R&ampD Day presentations. 

About Evaxion

Evaxion Biotech A/S is a pioneering corporation establishing AI-powered immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune method to learn and create novel immunotherapies for cancer, bacterial illnesses, and viral infections. Evaxion has a broad pipeline of candidates, such as 3 customized cancer immunotherapies. It is situated in Hørsholm, Denmark, with 50 staff listed on the Nasdaq New York stock exchange. For far more information and facts, please take a look at www.evaxion-biotech.com.

Forward-searching statement 
This announcement includes forward-searching statements inside the which means of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of comparable which means recognize forward-searching statements. Actual benefits might differ materially from these indicated by such forward-searching statements as a outcome of numerous things, such as, but not restricted to, dangers associated to: our economic situation and have to have for more capital our improvement function expense and good results of our solution improvement activities and preclinical and clinical trials commercializing any authorized pharmaceutical solution created working with our AI platform technologies, such as the price and degree of marketplace acceptance of our solution candidates our dependence on third parties such as for conduct of clinical testing and solution manufacture our inability to enter into partnerships government regulation protection of our intellectual house rights employee matters and managing development our ADSs and ordinary shares, the effect of international financial, political, legal, compliance, social and organization things, such as inflation, and the effects on our organization from the worldwide COVID-19 pandemic and the ongoing conflict in the area surrounding Ukraine and Russia and other uncertainties affecting our organization operations and economic situation. For a additional discussion of these dangers, please refer to the danger things integrated in our most current Annual Report on Kind 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are offered at www.sec.gov. We do not assume any obligation to update any forward-searching statements except as needed by law.